|1.||Palczewski, Krzysztof: 5 articles (08/2015 - 12/2007)|
|2.||Golczak, Marcin: 4 articles (08/2015 - 12/2014)|
|3.||Maeda, Akiko: 3 articles (03/2015 - 12/2007)|
|4.||Lu, Zheng-Rong: 2 articles (03/2015 - 12/2014)|
|5.||Gao, Song-Qi: 2 articles (03/2015 - 12/2014)|
|6.||Yu, Guanping: 2 articles (03/2015 - 12/2014)|
|7.||Veenstra, Alexander A: 1 article (08/2015)|
|8.||von Lintig, Johannes: 1 article (08/2015)|
|9.||Du, Yunpeng: 1 article (08/2015)|
|10.||Muthusamy, Arivalagan: 1 article (08/2015)|
01/01/2015 - "Here we investigated retinylamine and its derivatives to assess their inhibitor/substrate specificities for RPE65 and LRAT, mechanisms of action, potency, retention in the eye, and protection against acute light-induced retinal degeneration in mice. "
12/08/2014 - "Multifunctional PEG retinylamine conjugate provides prolonged protection against retinal degeneration in mice."
03/01/2015 - "Subcutaneous administration of the nanoparticles containing retinylamine provided a constant supply of the drug to the eye for about a week and resulted in effective prolonged prevention of light-induced retinal degeneration in DKO mice. "
03/01/2015 - "Prolonged prevention of retinal degeneration with retinylamine loaded nanoparticles."
12/04/2007 - "A2E accumulation and retinal degeneration were prevented by application of retinylamine, a potent retinoid cycle inhibitor. "
|2.||Macular Degeneration (Age-Related Maculopathy)
03/01/2015 - "Retinylamine nanoparticles hold promise for prolonged prophylactic treatment of human retinal degenerative diseases, including Stargardt disease and age-related macular degeneration."
03/01/2015 - "Here we achieved prolonged prevention of retinal degeneration by controlled delivery of retinylamine to the eye from polylactic acid nanoparticles in Abca4(-/-)Rdh8(-/-) (DKO) mice, an animal model of Stargardt disease/age-related macular degeneration. "
12/08/2014 - "A polyethylene glycol (PEG) retinylamine (Ret-NH2) conjugate PEG-GFL-NH-Ret with a glycine-phenylalanine-leucine (GFL) spacer was synthesized for controlled oral delivery of Ret-NH2 to treat retinal degenerative diseases, including Stargardt disease (STGD) and age-related macular degeneration (AMD). "
|3.||Retinitis Pigmentosa (Pigmentary Retinopathy)
|4.||Diabetic Retinopathy (Retinopathy, Diabetic)
08/28/2015 - "Retinylamine Benefits Early Diabetic Retinopathy in Mice."
|2.||Rhodopsin (Visual Purple)
|3.||Polyethylene Glycols (Polyethylene Glycol)
|6.||Glycine (Aminoacetic Acid)
|7.||poly(lactic acid) (polylactic acid)